# Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

> **NCT05505162** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 24 (actual)

## Conditions studied

- Healthy Female Participants

## Interventions

- **DRUG:** Zibotentan
- **DRUG:** EE/LNG

## Key facts

- **NCT ID:** NCT05505162
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-24
- **Primary completion:** 2023-01-10
- **Final completion:** 2023-01-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05505162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05505162, "Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05505162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*